1.Effects of Shengjiang Capsule on Gastric Evacuation in Rats
Weifeng SUN ; Tingli MAO ; Zhe DONG ; Lingbo SHI ; Ruzhenzhan GAO ;
Journal of Guangzhou University of Traditional Chinese Medicine 2001;0(03):-
ive] To observe the effects of Shengjiang Capsule (SC) on gastric evacuation and to study its mechanism. [Methods] Eight-week-old SD rats were randomly allocated to five groups. Group A served as normal control, and Group B were treated with high dosage of SC, Group C with low dosage of SC, Group D with Zhike Baizhu Decotion and Group E with cisapride. After ten days of treatment, gas tric evacuation of rats was detected by isotope tracing method, erythrocyte-acetycholinesterase activity by micro-hydroxylamine method and plasma motilin (Mot) and somatostatin (SS) levels by radioimmunoas-say. [Results] Thirty-minute gastric evacuation rate was (51.44?.38)%, (40.82 + 7.24)% and (40.22?.16)% in Group B, Group C and Group D respectively, which was higher than that in Group A [ (33.18?.32)%]. Erythrocyte-acetycholinesterase activity, Mot and SS levels were (0.856?.128) umol/h, (124.26?5.94) ng/L and (39.42?.96) ng/L, and (0.726?.164 ) umol/h, (119.86 ?9.38) ng/L and (38.33 ?.64) ng/L in Group B and Group C respectively, which were higher than those in Group A [ (0.576 ?.150)/umol/h, (91.28 + 26.84) ng/L and (28.22 ?7.68)ng/L]. [Conclusion] SC can promote gastric evacuation, and its mechanism may be re lated to the increase of the cholinergic nerve function and plasma Mot and SS levels.
2.Correlation between serum progesterone level at the day with human chorionic gonadotrophin administration and the outcome of pregnancy in in-vitro fertilization
Qiuping XI ; Yundong MAO ; Yan GAO ; Wei DING ; Wei WANG ; Xiang MA ; Feiyang DIAO ; Jie HUANG ; Xiaoqiao QIAN ; Lingbo CAI ; Ting FENG ; Zhengjie YAN ; Jiayin LIU
Chinese Journal of Obstetrics and Gynecology 2010;45(2):118-123
Objective To investigate the relationship between serum progesterone level at the day with human chorionic gonadotrophin (hCG) administration and pregnant outcome from in in-vitro fertilization-embryo transfer(IVF-ET). Methods From Mar. 2002 to Apr. 2007, 786 cycles with serum progesterone measurement on the day of hCG administration for final oocyte maturation in IVF were analyzed retrospectively in Reproductive Medicine Center in First Affiliated Hospital of Nanjing Medical University.All stimulations were down-regulated with gronadotrophin release hormone agonist (GnRH-a) in both long protocols and short protocols before gonadotrophin stimulation. When the thresholds of serum progesterone were set at 5.5, 6.0,6.5,7.0,7.5,8.0,8.5 and 9.0 nmol/L, respectively. If the level of progesterone was less than the thresholds, those patients were in lower progesterone group, on the contrary, more than the threshold value, those patients were in higher progesterone group. The laboratory results and the clinical outcomes between all patients at lower and higher progesterone group at different thresholds value were analyzed. Results The rate of normal fertilization, quality embryos, successful implantation, chemical pregnancy, clinical pregnancy and live birth did not exhibit remarkable difference between patients with higher and lower serum progesterone level at multiple thresholds on the day of hCG administration in the 786 cycles (P >0.05). However, when the thresholds of serum progesterone were at 8.5 and 9.0 nmol/L, early abortion rates of 27.3% (3/11) and 3/7 in higher progesterone group were significantly higher than 8.8% (26/297) and 8.6% (26/301) in lower progesterone group (P<0.05). And the total abortion rates of 3/7 in higher progesterone group were significantly higher than 11.0% (34/301) in lower progesterone group when the thresholds of serum progesterone were 9.0 nmol/L (P<0.05). Conclusions This study did not prove the correlationship between progesterone level at the clay with hCG administration and the probability of clinical pregnancy or live birth. However, early abortion rates or the total abortion rates were associated with higher progesterone level when the thresholds of serum progesterone were at 8.5 nmol/L or 9.0 nmoL/L.
3.The applied value of rescue intracytoplasmic sperm injection after complete fertilization failure during in vitro fertilization cycles.
Ting FENG ; Yun QIAN ; Jiayin LIU ; Yundong MAO ; Juan CHEN ; Lingbo CAI
National Journal of Andrology 2004;10(3):175-181
OBJECTIVETo discuss the applied value of rescue intracytoplasmic sperm injection(ICSI) after complete fertilization failure during in vitro fertilization (IVF) cycles.
METHODSAfter 16-18 h co-culture with sperm, all the unfertilized oocytes with the first polar body were re-fertilized by ICSI.
RESULTSAfter rescue ICSI, the abnormal fertilization rate was 17.9% and the normal fertilization rate was 42.7%. Twenty-four hours later, the normal cleavage rate of the normal fertilized oocytes was 79.6%. On the day of embryo transfer, the good-quality rate of embryos was 29.7% (22/74). A mean number of 3.4 (54/16) embryos were transferred to the patient during each cycle. Clinical pregnancy was found in 3 cases out of the 16 (18.8%).
CONCLUSIONThe applied value of rescue ICSI may be correlated with the number and maturity of oocytes on the retrieval day.
Female ; Fertilization ; Fertilization in Vitro ; Humans ; Infant, Newborn ; Male ; Pregnancy ; Sperm Injections, Intracytoplasmic
4.Clinical treatment of postmenopausal female urethral syndrome with promestriene vaginal gelatin capsules administered through different schemes
Dong ZHU ; Yuehua LAO ; Lingbo MAO ; Yong HUANG ; Xian WANG
Chinese Journal of Primary Medicine and Pharmacy 2023;30(9):1319-1323
Objective:To investigate the efficacy and safety of promestriene vaginal gelatin capsules administered through different schemes in the treatment of postmenopausal female urethral syndrome.Methods:A total of 120 patients with postmenopausal female urethral syndrome who received treatment in General Hospital of Medical and Health Group of Cixi Third People's Hospital from January 2021 to June 2022 were included in this study. They were randomly divided into groups A and B ( n = 60/group). Group A was treated with vaginal gelatin capsules containing 10 mg promestriene once a day. Group B was treated with vaginal gelatin capsules containing 10 mg promestriene twice a day. Both groups were treated for 20 days as a course of treatment. The improvement of symptoms, lower urinary tract symptom score, quality of life score, estradiol level, follicle stimulating hormone level, and endometrial thickness were compared between the two groups. Results:After treatment, the scores of incomplete urination, urination interval, intermittent urination, dysuria, thinner urine line, urination force, and nocturnal urination times in group A were (2.51 ± 1.76) points, (2.66 ± 1.08) points, (2.61 ± 1.45) points, (2.48 ± 1.42) points, (2.85 ± 1.03) points, (2.48 ± 1.42) points, and (2.52 ± 1.72) points, respectively, which were significantly lower than (3.15 ± 1.35) points, (3.23 ± 1.14) points, (2.99 ± 1.57) points, (3.08 ± 1.09) points, (3.45 ± 1.72) points, (3.25 ± 1.08) points, and (3.21 ± 1.87) points, respectively, in group B ( t = 10.57, 9.78, 13.83, 10.34, 9.35, 12.34, 9.45, all P < 0.05). The quality of life score in group A was (2.45 ± 0.86) points, which was significantly lower than (3.51 ± 0.92) points in group B ( t = 5.45, P < 0.05). There were no significant differences in estradiol and follicle stimulating hormone levels and endometrial thickness between the two groups before and after treatment (all P > 0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion:Local application of promestriene vaginal gelatin capsules can improve the urethral syndrome in postmenopausal women. The once daily 10 mg promestriene vaginal gelatin capsule administration scheme can achieve better efficacy and safety than the twice daily administration scheme. The study is innovative, scientific, and worthy of clinical promotion.